These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 2902655

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
    McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A.
    N Engl J Med; 1996 Jan 25; 334(4):220-4. PubMed ID: 8531998
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
    El Refaei SM, Shawkat W.
    Nucl Med Commun; 2008 Jul 25; 29(7):642-8. PubMed ID: 18528187
    [Abstract] [Full Text] [Related]

  • 6. Thyroid stimulating immunoglobulins in patients in long-term remission after Graves' disease.
    Bliddal H, Bech K, Kirkegaard C.
    Horm Metab Res; 1984 Nov 25; 16(11):602-5. PubMed ID: 6210237
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
    Li J, Gao H, Xu L.
    Zhonghua Yi Xue Za Zhi; 1994 Apr 25; 74(4):218-20, 254-5. PubMed ID: 7922762
    [Abstract] [Full Text] [Related]

  • 12. Thyrotrophin binding inhibiting immunoglobulins in Graves' disease before, during and after antithyroid therapy, and its relation to long-acting thyroid stimulator.
    Docter R, Bos G, Visser TJ, Hennemann G.
    Clin Endocrinol (Oxf); 1980 Feb 25; 12(2):143-53. PubMed ID: 6105023
    [Abstract] [Full Text] [Related]

  • 13. T lymphocyte subsets at various stages of hyperthyroid Graves' disease: effect of carbimazole treatment and relationship with thyroid-stimulating antibody levels or HLA status.
    Madec AM, Allannic H, Genetet N, Gueguen M, Genetet G, Fauchet R, Stefanutti A, Orgiazzi J.
    J Clin Endocrinol Metab; 1986 Jan 25; 62(1):117-21. PubMed ID: 3484386
    [Abstract] [Full Text] [Related]

  • 14. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T, Holle LH, Schroth HJ, Garth H.
    Nuklearmedizin; 1998 May 25; 37(3):90-4. PubMed ID: 9604228
    [Abstract] [Full Text] [Related]

  • 15. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Esser J, Morgenthaler NG.
    Clin Endocrinol (Oxf); 2004 Nov 25; 61(5):612-8. PubMed ID: 15521965
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Long-term evolution of immunologic and thyroid function in Graves disease according different therapeutic options].
    Campos Pastor MM, Fernández Soto ML, Escobar-Jiménez F, Barredo Acedo F, Ruiz de Almodóvar M.
    Med Clin (Barc); 1994 Apr 02; 102(12):446-50. PubMed ID: 7516033
    [Abstract] [Full Text] [Related]

  • 18. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration.
    Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y, Le Guerrier AM, Delambre C, Derennes V.
    J Clin Endocrinol Metab; 1990 Mar 02; 70(3):675-9. PubMed ID: 1689737
    [Abstract] [Full Text] [Related]

  • 19. Detectability of thyroid anti-microsomal antibodies, changes in thyroid-stimulating immunoglobulins (TSI) and thyrotropin-binding-inhibiting immunoglobulins (TBII) during methimazole treatment of Graves' disease patients.
    Szabó J, Leövey A, Karányi Z, Várvölgyi C, Fórizs E, Herceg L.
    Acta Med Hung; 1989 Mar 02; 46(1):23-30. PubMed ID: 2570399
    [Abstract] [Full Text] [Related]

  • 20. Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease.
    Edan G, Massart C, Hody B, Poirier JY, Lé Reun M, Hespel JP, Leclech G, Simon M.
    BMJ; 1989 Feb 11; 298(6670):359-61. PubMed ID: 2564286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.